MENU
+Compare
GERN
Stock ticker: NASDAQ
AS OF
Oct 17 closing price
Price
$1.20
Change
-$0.03 (-2.44%)
Capitalization
765.62M

GERN Geron Corp Forecast, Technical & Fundamental Analysis

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments... Show more

Industry: #Biotechnology
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for GERN with price predictions
Oct 17, 2025

GERN in downward trend: 10-day moving average crossed below 50-day moving average on October 06, 2025

The 10-day moving average for GERN crossed bearishly below the 50-day moving average on October 06, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 13, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GERN as a result. In of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for GERN turned negative on October 13, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

GERN moved below its 50-day moving average on October 10, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GERN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GERN broke above its upper Bollinger Band on October 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GERN entered a downward trend on September 23, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GERN advanced for three days, in of 213 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. GERN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.950) is normal, around the industry mean (24.230). P/E Ratio (0.000) is within average values for comparable stocks, (54.529). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.181). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (4.850) is also within normal values, averaging (349.879).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GERN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

GERN is expected to report earnings to rise 26.50% to -2 cents per share on November 06

Geron Corp GERN Stock Earnings Reports
Q3'25
Est.
$-0.03
Q2'25
Beat
by $0.01
Q1'25
Est.
$-0.03
Q4'24
Missed
by $0.01
Q3'24
Beat
by $0.04
The last earnings report on August 06 showed earnings per share of -1 cents, beating the estimate of -2 cents. With 5.25M shares outstanding, the current market capitalization sits at 765.62M.
A.I. Advisor
published General Information

General Information

a developer of therapeutic products for cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
919 East Hillsdale Boulevard
Phone
+1 650 473-7700
Employees
141
Web
https://www.geron.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ISTIX92.83N/A
N/A
Macquarie Science and Technology I
JMCGX29.83N/A
N/A
Jacob Discovery Fd Inv
PZVIX13.06N/A
N/A
Pzena International Small Cap Value Inv
RYPCX7.25-0.02
-0.28%
Royce Small-Cap Fund Consult
REBYX26.33-0.09
-0.34%
Russell Inv US Small Cap Equity Y

GERN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
-2.44%
SER - GERN
66%
Loosely correlated
-1.68%
LIANY - GERN
53%
Loosely correlated
+5.83%
VCYT - GERN
44%
Loosely correlated
+0.06%
SYRE - GERN
38%
Loosely correlated
+1.03%
BMRN - GERN
38%
Loosely correlated
+0.64%
More